Evidence Hub

AB0817 CAN statines improve bone quality in posmenopausal osteoporosis?

P. Astesana, P. Alba, C. Gobbi, R. Fernández, E. Albiero, M. Yorio

Abstracts Accepted for Publication, 2019

202 participants

Abstract

Background Osteoporosis (OP) is the most frequent metabolic bone disease. It has low bone mass and microarchitectural deterioration, which increases the risk of fractures. The most commonly used drugs are bisphosphonates, however statins (ST) have pleiotropic properties, and some researchers suggested their use in OP. Objectives To determine the effect of ST on bone mineral density (BMD) in postmenopausal osteoporotic women. Methods A cross-sectional study, control case where postmenopausal women with hypercholesterolemia treated with ST for a period not less than 6 months were studied for two years. The control group was postmenopausal population that did not receive statins. Exclusion criteria: Diabetes, previous treatment with estrogen, calcitonin, anabolic, steroids, bisphosphonates or vitamin D during a period of 6 months prior to enter to the study or with amenorrhea less than 12 months. We evaluated age, weight, height, BMI, personal and first degree family members’ history of fracture, use of corticosteroids, smoking, alcoholism, daily calcium intake, sedentary lifestyle, phosphocalcic metabolism laboratory and Vitamin D. All patients were performed Bone Densitometry by dual-energy X-ray absorptiometry (DXA) with an Hologic equipment in right hip and lumbar spine, staging them according to WHO. The statistical analysis was performed using the Student’s test and the Fisher test for categorical variables. Values of p less than 0.05 were considered significant. Results…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free